China Regenerative Medicine International (HKSE:08158) Growth Rank : 1 (As of Jan. 18, 2025)

View and export this data going back to 2001. Start your Free Trial

What is China Regenerative Medicine International Growth Rank?

China Regenerative Medicine International has the Growth Rank of 1.

GuruFocus Growth Rank measures the growth of a company in terms of its revenue and profitability. Historically, the companies with the highest growth ranks performed the best over the long term. It is calculated using the following criteria:

1. 5-year revenue growth rate, the higher, the better.
2. 3-year revenue growth rate, the higher, the better.
3. 5-year EBITDA growth rate, the higher, the better.
4. The predictability of 5-year revenue. The most consistent it is, the higher the rank.

GuruFocus found that the Growth Rank is the second of the two most-sensitive parameters among the five parameters checked. Please click GF Score to see more details on GF Score's 5 Key Aspects of Analysis.

Please note that we are using the five-year EBITDA growth rate as a parameter, so the company needs to have had positive growth over that time. The reason we use EBITDA instead of earnings per share is that with EBITDA, we can rank a lot more companies since a company may have positive EBITDA but negative EPS. Since we are looking at the growth here, EBITDA gives us a pretty clear picture about the growth in the company's business operations.

Competitive Comparison of China Regenerative Medicine International's Growth Rank

For the Biotechnology subindustry, China Regenerative Medicine International's Growth Rank, along with its competitors' market caps and Growth Rank data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.

China Regenerative Medicine International's Growth Rank Distribution in the Biotechnology Industry

For the Biotechnology industry and Healthcare sector, China Regenerative Medicine International's Growth Rank distribution charts can be found below:

* The bar in red indicates where China Regenerative Medicine International's Growth Rank falls into.

China Regenerative Medicine International Growth Rank Related Terms

Thank you for viewing the detailed overview of China Regenerative Medicine International's Growth Rank provided by GuruFocus.com. Please click on the following links to see related term pages.

China Regenerative Medicine International Business Description

Industry

GURUFOCUS.COM » STOCK LIST » Healthcare » Biotechnology » China Regenerative Medicine International Ltd (HKSE:08158) » Definitions » Growth Rank

Comparable Companies

Traded in Other Exchanges

N/A

Address

132 Nathan Road, Suite 2310–18, Miramar Tower, Tsim Sha Tsui, Kowloon, HKG

Website

https://www.crmi.hk

China Regenerative Medicine International Ltd is an investment holding company engaged in the provision of healthcare products and services. Its reportable segments are Aesthetic medical and beauty services and Medical services. The vast majority of the company's revenue is derived from its Aesthetic medical and beauty services segment. Geographically, the People's Republic of China accounts for the majority of the revenue. It also has a presence in Hong Kong.

Executives

Wang Chuang	2101 Beneficial owner
Wong Kwok Keung	2501 Other
Arab Osman Mohammed	2501 Other
Chang Zhou Shi Zhong Min Xing Kong Qi Ye Guan Li Zi Xun Fu Wu He Huo Qi Ye You Xian He Huo	2201 Interest of corporation controlled by you
Lei Changjuan	2101 Beneficial owner
Chang Zhou Shi Yao Guang Qi Ye Guan Li Zi Xun He Huo Qi Ye You Xian He Huo	2201 Interest of corporation controlled by you
Kong Yudong	2101 Beneficial owner
Li Ren	2201 Interest of corporation controlled by you
Nat-ace Wood Industry Ltd. (formerly Known As Forerunner Technology Limited)	2201 Interest of corporation controlled by you
All Favour Holdings Limited	2101 Beneficial owner
Deng Shufen	2202 Interest of your spouse
Dai Yumin	2201 Interest of corporation controlled by you
Wang Xiaogang	2101 Beneficial owner
China Orient Asset Management Co., Ltd.	2106 Person having a security interest in shares
China Orient Alternative Investment Fund	2106 Person having a security interest in shares

China Regenerative Medicine International Headlines

No Headlines